Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics (NKTR) has announced its upcoming participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025. The company will host a fireside chat at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time).
The presentation will be accessible through a webcast link and the Investor Events section of Nektar's website. Interested parties can access the replay for 30 days following the event. One-on-one meetings with management can be arranged through H.C. Wainwright representatives.
Nektar Therapeutics (NKTR) ha annunciato la sua prossima partecipazione alla 3ª Conferenza Virtuale Annuale sulle Malattie Autoimmuni e Infiammatorie di H.C. Wainwright che si terrà giovedì 27 marzo 2025. L'azienda ospiterà una chiacchierata informale alle 14:00 ora orientale (11:00 ora del Pacifico).
La presentazione sarà accessibile tramite un link al webcast e nella sezione Eventi per Investitori del sito web di Nektar. Le parti interessate potranno accedere alla registrazione per 30 giorni dopo l'evento. È possibile organizzare incontri individuali con la direzione tramite i rappresentanti di H.C. Wainwright.
Nektar Therapeutics (NKTR) ha anunciado su próxima participación en la 3ª Conferencia Virtual Anual sobre Enfermedades Autoinmunes e Inflamatorias de H.C. Wainwright que se llevará a cabo el jueves 27 de marzo de 2025. La compañía realizará una charla informal a las 2:00 p.m. hora del Este (11:00 a.m. hora del Pacífico).
La presentación será accesible a través de un enlace de webcast y en la sección de Eventos para Inversores del sitio web de Nektar. Las partes interesadas podrán acceder a la repetición durante 30 días después del evento. Se pueden organizar reuniones individuales con la dirección a través de los representantes de H.C. Wainwright.
넥타 Therapeutics (NKTR)는 H.C. Wainwright 제3회 자가면역 및 염증 질환 가상 회의에 참여할 예정임을 발표했습니다. 회의는 2025년 3월 27일 목요일에 열립니다. 회사는 동부 표준시 기준 오후 2시(태평양 표준시 기준 오전 11시)에 화상 대화를 진행할 것입니다.
발표는 웹캐스트 링크와 넥타 웹사이트의 투자자 이벤트 섹션을 통해 접근할 수 있습니다. 관심 있는 분들은 이벤트 후 30일 동안 재생을 이용할 수 있습니다. H.C. Wainwright의 대표를 통해 경영진과의 일대일 미팅을 조율할 수 있습니다.
Nektar Therapeutics (NKTR) a annoncé sa prochaine participation à la 3ème Conférence Virtuelle Annuelle sur les Maladies Auto-immunes et Inflammatoires de H.C. Wainwright, qui se tiendra le jeudi 27 mars 2025. La société animera une discussion informelle à 14h00, heure de l'Est (11h00, heure du Pacifique).
La présentation sera accessible via un lien de webcast et dans la section Événements pour Investisseurs du site web de Nektar. Les parties intéressées pourront accéder à la rediffusion pendant 30 jours après l'événement. Des réunions individuelles avec la direction peuvent être organisées par l'intermédiaire des représentants de H.C. Wainwright.
Nektar Therapeutics (NKTR) hat seine bevorstehende Teilnahme an der 3. Virtuellen Jahreskonferenz zu Autoimmun- und Entzündungserkrankungen von H.C. Wainwright am Donnerstag, den 27. März 2025 angekündigt. Das Unternehmen wird um 14:00 Uhr Eastern Time (11:00 Uhr Pacific Time) ein informelles Gespräch veranstalten.
Die Präsentation wird über einen Webcast-Link und im Bereich Investorenevents auf der Website von Nektar zugänglich sein. Interessierte Parteien können die Wiederholung 30 Tage nach der Veranstaltung abrufen. Einzelgespräche mit dem Management können über die Vertreter von H.C. Wainwright arrangiert werden.
- None.
- None.
- H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contact:
For Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-hc-wainwright-3rd-annual-autoimmune--inflammatory-disease-virtual-conference-302407356.html
SOURCE Nektar Therapeutics
FAQ
When is Nektar Therapeutics (NKTR) presenting at the H.C. Wainwright Conference 2025?
How long will the NKTR conference presentation replay be available?
Where can investors access Nektar's (NKTR) H.C. Wainwright conference presentation?
How can investors arrange one-on-one meetings with NKTR management during the conference?
